AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02383758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl suppository
Description: If a subject does not have a bowel movement during the 30 minute sit following administration of the glycerin suppository, they will be given a 1 hour break, after which a bisacodyl suppository will be administered. The participant will then sit for an additional 30 minutes.If continent bowel movements maintain for two subsequent days (after senna is discontinued) bisacodyl suppositories will be discontinued if it was required. At least one primary caregiver will be trained on all components of intervention still in use on the last day their child's admission. Four weekly follow-up appointments will be used to support them as they continue to implement the protocol at home, including continuing to fade out the use of medications for participants who are at least partially continent but not fully independent at the time of discharge.
Study NCT02383758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisacodyl suppository
Description: If a subject does not have a bowel movement during the 30 minute sit following administration of the glycerin suppository, they will be given a 1 hour break, after which a bisacodyl suppository will be administered. The participant will then sit for an additional 30 minutes.If continent bowel movements maintain for two subsequent days (after senna is discontinued) bisacodyl suppositories will be discontinued if it was required. At least one primary caregiver will be trained on all components of intervention still in use on the last day their child's admission. Four weekly follow-up appointments will be used to support them as they continue to implement the protocol at home, including continuing to fade out the use of medications for participants who are at least partially continent but not fully independent at the time of discharge.
Study NCT02383758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Senna
Description: If no continent bowel movements occur for two consecutive treatment days, caregivers will be asked to administer senna each evening thereafter until medication tapering begins. Once there have been two successive days with continent bowel movements, senna will be removed from the intervention if it was required.
Study NCT02383758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Senna
Description: If no continent bowel movements occur for two consecutive treatment days, caregivers will be asked to administer senna each evening thereafter until medication tapering begins. Once there have been two successive days with continent bowel movements, senna will be removed from the intervention if it was required.
Study NCT04302571 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: combined aerobic and resistance physical activity
Description: Five training sessions weekly for 12 weeks are scheduled. Each session lasts 60 minutes divided into 45 minutes of aerobic workout and 15 minutes of circuit training. The aerobic workout consists of walking on a flat floor or on a slight uphill (maximum slope 3%): patients should walk until submaximal walking capacity (80% of their MWT) and rest as they would experience pain at the lower limbs; afterwards, they should start to walk again, once the pain was improved. Resistance training consists of calisthenics exercises focused on trunk and lower limbs muscles (bicycle, flutter kicks, squats, lunges, calf raises, wall sits and power press) with at least 3 repetitions for each exercise, interspersed by 30 seconds recovery. Duration of repetitions increases every 3 weeks.
Study NCT04302571 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: sham exercise
Description: general recommendation to perform regular aerobic physical activity
Study NCT03798431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: M-ROCC
Description: 1. LDM (Low-Dose Mindfulness): A 4-wk intro mindfulness program for OUD, 50 min/week including explicit training in use of mobile mindfulness apps, with rolling admission and ascending practice dose ladder.~2. MTPC (Mindfulness Training for Primary Care): An eight-week intensive mindfulness group with ascending practice dose ladder and skill integration over 8 weeks \& 120 minutes/wk.~3. MCS (Mindfulness Maintenance Check-in Support): Ongoing weekly mindfulness group with check-in and reminders, leveraging mobile mindfulness apps and motivational counseling for grads of LDM for 50 mins/wk.~After completion of the LDM group, participation in various levels is fluid based on patient motivation, choice, and readiness.
Study NCT02242877 — intervention group
Intervention type: DRUG
Intervention: Telmisartan
Study NCT02242877 — intervention group
Intervention type: DRUG
Intervention: Telmisartan combined with hydrochlorothiazide
Study NCT04251559 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oral glucose loading test
Description: oral glucose loading test was performed to all participants. gestational diabetes and control group were compared in terms of menarche age.
Study NCT04251559 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral glucose loading test
Description: oral glucose loading test was performed to all participants. gestational diabetes and control group were compared in terms of menarche age.
Study NCT04849949 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants in this group received a traditional muffin with butter as the predominant source of fat.
Study NCT04849949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black walnut
Description: Participants in this group received a muffin in which part of the butter was substituted out for black walnuts.
Study NCT04849949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: English walnut
Description: Participants in this group received a muffin in which part of the butter was substituted out for English walnuts.
Study NCT04258839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Oral tablet; taken once daily
Study NCT03488576 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complete Macular Peeling
Description: A complete peeling of the internal limiting membrane was performed
Study NCT03488576 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Macular Peeling with Foveal Sparing
Description: A partial peeling of the internal limiting membrane was performed, sparing the fovea.
Study NCT01175824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro Low Mixture (LM)
Description: Participant-dependent dose, administered subcutaneously for 24 weeks
Study NCT01175824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Participant-dependent dose, administered subcutaneously for 24 weeks
Study NCT01175824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prandial Insulin Lispro
Description: Participant-dependent dose, administered subcutaneously for 24 weeks
Study NCT02970968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLY-686 (Tradipitant)
Description: oral capsule
Study NCT02970968 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo oral
Study NCT04453852 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID19 vaccine
Description: COVID19 recombinant spike protein with Advax-SM adjuvant
Study NCT04453852 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline control
Study NCT04466514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX029
Description: Form: tablet; Route of Administration: oral
Study NCT03444857 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Description: The optimal continuous positive airway pressure (CPAP, AutoSet S9, ResMed, Sydney, Australia) settings will be determined during 1-2 nights within 7 days after pPCI.
Study NCT01816139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Vehicle Cream applied to the vagina daily for 2 weeks followed by dosing 2 times a week for 10 weeks
Study NCT01816139 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: WC3011 Estradiol Vaginal Cream
Description: WC3011 estradiol vaginal cream applied daily for 2 weeks followed by dosing 2 times a week for 10 weeks
Study NCT02537080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimodipine group
Description: the stability of the blood pressure will be managed in interval plus minus 15% of patient's resting blood pressure
Study NCT02537080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control group
Description: the stability of the blood pressure will be managed in interval plus minus 15% of patient's resting blood pressure
Study NCT01111656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta-1b group
Description: Patients receive interferon beta-1b 250ug subcutaneously every other day
Study NCT01111656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b/Atorvastatin group
Description: Patients receive interferon beta-1b 250ug subcutaneously every other day AND atorvastatin 40mg every day (oral)
Study NCT02786615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Unity
Description: A 4-session, group-delivered intervention focusing on peer/social network-based recruitment and referral program to receive HIV prevention and treatment services in the community.
Study NCT06219655 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracoscopic sympathectomy
Description: sympathectomy
Study NCT01360034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine
Description: Nifedipine: 20 mg as a single dose upon admission and then 10 mg vo every 8 hours for 48 hours.
Study NCT01360034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: Indomethacin: 50 mg vo as a single dose upon admission and then 25 mg vo every 6 hours for 48 hours.
Study NCT02012387 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active
Description: Two injections will be administered every four weeks for four months, we will administer 4 doses within 16 weeks
Study NCT02554331 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FP-CIT single-photon emission computed tomography
Description: FP-CIT radiolabeled is used as a surrogate marker to examine the integrity of the dopaminergic nigrostriatal neurons.
Study NCT02554331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: neuropsychological evaluation
Description: Assessment of:~* overall cognitive function~* executive functions~* visuospatial functions~* Nonverbal memory~* verbal memory~* Evaluation of hearing ability of time perception and sensorimotor synchronization from selected tasks the Battery of assessment of auditory sensorimotor and timing abilities~* Beck Depression Inventory
Study NCT02554331 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: neuropsychological evaluation
Description: Assessment of:~* overall cognitive function~* executive functions~* visuospatial functions~* Nonverbal memory~* verbal memory~* Evaluation of hearing ability of time perception and sensorimotor synchronization from selected tasks the Battery of assessment of auditory sensorimotor and timing abilities~* Beck Depression Inventory
Study NCT02554331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait recording with sensors
Description: Gait recording with sensors
Study NCT02012387 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two injections will be administered every four weeks for four months, we will administer 4 doses within 16 weeks
Study NCT02012387 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Open labeled
Description: Two injections will be administered every four weeks for 8 months, we will administer 4 doses within 32 weeks
Study NCT04380584 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: plasma Apelin level
Description: blood sample for detection of plasma Apelin level
Study NCT02037503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Study NCT02037503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Study NCT02037503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT00785226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA119
Description: Total daily doses of RDEA119 from 10 mg/day to 100 mg/day
Study NCT02554331 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Gait recording with sensors
Description: Gait recording with sensors
Study NCT04571164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03003(Rotigotine,extended-release microspheres)
Description: During the intervention, the initial dose was 14mg, and then was incremented in weekly units, 14mg each time, until the maximum dose of 56mg set in this study was reached 4 weeks after titration, the optimal therapeutic dose or the maximum tolerated dose was entered into the dosing maintenance period. After entering the maintenance period, no dose adjustment was performed, and the stable dose was maintained for 24 weeks
Study NCT00785226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Total daily doses of sorafenib from 400 mg/day to 800 mg/day.
Study NCT04898218 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The exercises were performed for 12 weeks, for the maximum of 6 days/week for Osteoanabolic group, 5 days/week for aerobic group and 3 days/ week for a resistance group as per ACSM, FITT protocol.
Study NCT04898218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercises were performed for 12 weeks, for the maximum of 6 days/week for Osteoanabolic group, 5 days/week for aerobic group and 3 days/ week for a resistance group as per ACSM, FITT protocol.
Study NCT03563040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxsalen
Description: Methoxsalen is used in conjunction with the THERAKOS CELLEX Photopheresis System.~During each photopheresis treatment with methoxsalen, the dosage of methoxsalen is calculated according to the treatment volume (which is displayed on the display panel of the instrument) using the formula:~Treatment volume x 0.017 ml of methoxsalen (20 µg/mL) for each treatment For example: Treatment volume = 240 mL x 0.017 = 4.1 mL of methoxsalen (20 µg/mL)
Study NCT03563040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERAKOS CELLEX Photopheresis System
Description: Methoxsalen is used in conjunction with the THERAKOS CELLEX Photopheresis System.
Study NCT03384446 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tooth-borne treatment
Description: Titanium curettes
Study NCT03384446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implant-specific treatment
Description: Implant brush
Study NCT01310413 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H5N1) Virus monovalent vaccine
Description: All subjects will receive 2 doses administered as an intramuscular (IM) injection.
Study NCT01310413 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: All subjects will receive 2 doses administered as an intramuscular (IM) injection.
Study NCT04571164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo,extended-release microspheres
Description: During the intervention,the initial does was 14mg,and then was incremented in weekly units,14mg each time,until the maximum does of 56mg set in this study was reached 4 weeks after titration,the optimal therapeutic does or the maximum tolerated does was entered into the dosing maintenance period.After entering the maintenance period,no does adjustment was performed,and the stable does was maintained for 24 weeks.
Study NCT03001427 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured center-based lifestyle intervention
Study NCT03001427 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard education and physician advice
Study NCT01906931 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable oxygen concentrator
Description: Respironics EverGo portable oxygen concentrator on setting 6
Study NCT03724604 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuron-Specific Enolase to Albumin Ratio
Description: Previous studies have shown that inflammation and nutrition-related factors such as CRP/Alb (C-reactive protein-albumin ratio), PLR (platelet-to-lymphocyte ratio), NLR (neutrophil-to-lymphocyte ratio) can help to assess the prognosis of malignant tumors. This study is the first time to combine NSCLC tumor marker NSE and patient nutrition-related indicators Alb to predict the prognosis of patients, trying to find high sensitivity and specificity for NSCLC prognostic indicators to guide clinical work.
Study NCT03405467 — intervention group
Intervention type: OTHER
Intervention: general and specific data
Description: General and specific data collected
Study NCT01906931 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Portable oxygen concentrator
Description: Respironics EverGo portable oxygen concentrator on setting 6
Study NCT00678600 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard (static) Computer Alerts
Description: Static Computer Alerts on Patient's EMR webpage.
Study NCT00678600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Computer Alerts
Description: Population level and asynchronous alerts with enhanced functionality
Study NCT04448860 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: performance of behavioral locomotion tasks phase 1
Description: The performance of behavioral locomotion tasks is performed on 4 visits on pilot phase (2 in real condition and 2 in virtual reality in D1 and M1)
Study NCT04448860 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: performance of behavioral locomotion tasks phase 2
Description: The performance of behavioral locomotion tasks is performed on 6 visits on validation phase (3 in real condition and 2 in virtual reality in D1, M1 and M12)
Study NCT04448860 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: performance of behavioral locomotion tasks phase 2
Description: The performance of behavioral locomotion tasks is performed on 6 visits on validation phase (3 in real condition and 2 in virtual reality in D1, M1 and M12)
Study NCT05252026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROCARE-I (UP-A for indicated purposes)
Description: This intervention is meant to respond to the heterogeneity inherent in emotional difficulties presentation by extinguishing distress associated with the presentation of heightened negative emotion in general and reduction or elimination of resultant emotionally-driven behaviours, including avoidance, escape, aggression, and controlling behaviours (e.g., reassurance seeking) that reinforce emotional distress intensity over time.
Study NCT05252026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active control condition
Description: Psychoeducation about many different emotions, emphasis on discussing thoughts, feelings, and behavior as parts of emotion, and emphasis on providing support around generally distressing events.
Study NCT01643473 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Intervention
Description: Patients randomized to the TAI group will complete a tailoring survey at the baseline visit to identify the most salient adherence barriers to the individual, which will be used to create an individualized adherence profile. Following completion of the tailoring survey, patients will collaborate with the RA to identify the most suitable mix of intervention strategies for improving medication adherence (i.e., reminder aids, motivational interviewing, case management) that are matched to the barriers outlined on patients' individualized adherence profiles.
Study NCT01643473 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Health education videos on topics unrelated to medication adherence, hypertension or type 2 diabetes
Study NCT03205085 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: assessment of right heart dimensions and function by cardiac magnetic resonance Imaging.
Study NCT03205085 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2D and 3D trans-thoracic echocardiography
Description: assessment of right heart dimensions and function by 2D and 3D trans-thoracic echocardiography
Study NCT03205085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood samples for assays of immune inflammatory biomarkers (InterLeukin-18, CXCL9 or interferon
Study NCT00569972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0200390
Description: Capsules, 45 mg, 3 capsules each night before bedtime, Duration- Visit 3-7 for 28 days
Study NCT00569972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0200390
Description: Capsules, 60 mg, 3 capsules each night before bedtime, Duration - Visit 3-7 for 28 days
Study NCT03603886 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine Pain Management Intervention (immediate group)
Description: Four weekly telemedicine pain management sessions with a trained provider. Intervention will be delivered via video conferencing platform, and each session will last between 30 and 45 minutes. Intervention topics will include: pain psychoeducation, pain coping tools, pain communication, and pain-related stress management.